US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NewcelX Ltd.

2.77

+0.13004.92%

Post-market: 2.770.00000.00%18:14 EST

Volume:14.86K

Turnover:40.51K

Market Cap:12.63M

PE:-0.64

High:2.84

Open:2.70

Low:2.64

Close:2.64

52wk High:30.80

52wk Low:1.89

Shares:4.56M

Float Shares:4.56M

Volume Ratio:0.25

T/O Rate:0.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.3226

EPS(LYR):-1.7386

ROE:--

ROA:-155.19%

PB:-0.92

PE(LYR):-1.59

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

NewcelX AG Releases Updated Corporate Presentation

NewcelX AG Reports Positive Results from International Study on Stem Cell-Derived Islet Therapy for Type 1 Diabetes

Newcelx Appoints DR. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

THOMSON REUTERS

Press Release: NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCEL"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":2.77,"timestamp":1770411600000,"preClose":2.64,"halted":0,"volume":14861,"hourTrading":{"tag":"盘后","latestPrice":2.77,"preClose":2.77,"latestTime":"18:14 EST","volume":22,"amount":61.94,"timestamp":1770419697068,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0492424242424242,"floatShares":4558400,"shares":4558400,"eps":-4.322621,"marketStatus":"Market Closed","change":0.13,"latestTime":"02-06 16:00:00 EST","open":2.7,"high":2.84,"low":2.64,"amount":40514.5681,"amplitude":0.075758,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.322621,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":2.64,"preHourTrading":{"tag":"盘前","latestPrice":2.64,"preClose":2.64,"latestTime":"07:11 EST","volume":10,"amount":26.400000000000002,"timestamp":1770379911510,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.77,"preClose":2.77,"latestTime":"18:14 EST","volume":22,"amount":61.94,"timestamp":1770419697068,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.2457922461020662},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":4558400,"roa":"-155.19%","roe":"--","lyrEps":-1.738588,"volumeRatio":0.2457922461020662,"shares":4558400,"dividePrice":0,"high":2.84,"amplitude":0.075758,"preClose":2.64,"low":2.64,"week52Low":1.89,"pbRate":"-0.92","week52High":30.799,"institutionHeld":0,"latestPrice":2.77,"eps":-4.322621,"divideRate":0,"volume":14861,"delay":0,"ttmEps":-4.322621,"open":2.7,"prevYearClose":1.9,"prevWeekClose":2.6,"prevMonthClose":2.6,"prevQuarterClose":1.9,"fiveDayClose":2.6,"twentyDayClose":2.21,"sixtyDayClose":3.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-02-06","current":-0.640815,"percent":0.646154,"low":-2.085416,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"high":-0.442896,"avg":-0.742563,"sd":0.254039,"marketCap":12034117},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117}],"updateTime":1770461309757},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607808112","title":"NewcelX AG Releases Updated Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2607808112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607808112?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:02","pubTimestamp":1769688131,"startTime":"0","endTime":"0","summary":"NewcelX AG has released an updated corporate presentation ahead of key spring 2026 investor and partnering conferences, highlighting its strategic focus on Type 1 Diabetes cell therapy and recent additions to its Scientific Advisory Board and leadership team. The updated presentation is available on the Company's website at: Corporate Presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL6l1Sz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","LU0077335932.USD","LU2491050071.SGD","LU1267930490.SGD","LU2552382215.SGD","IE00BJJMRZ35.SGD","BK4534","LU0052756011.USD","LU1548497426.USD","LU0048584097.USD","LU0211327993.USD","LU1057294990.SGD","LU2023251221.USD","LU0097036916.USD","LU0528227936.USD","LU0029864427.USD","LU2491049909.HKD","SGXZ31699556.SGD","LU2347655156.SGD","LU0114720955.EUR","LU2111349929.HKD","SGXZ81514606.USD","LU2361044949.HKD","LU0965509101.SGD","IE0004445239.USD","LU0053666078.USD","LU0820561909.HKD","LU0310800379.SGD","LU0976567544.SGD","LU1989771016.USD","NCEL","IE00BJJMRX11.SGD","IE00B1BXHZ80.USD","IE00B2B36J28.USD","LU1732799900.SGD","SGXZ99366536.SGD","IE00BFTCPJ56.SGD","LU1267930573.SGD","LU0965509283.SGD","LU1670628061.USD","UNHG","IE000M9KFDE8.USD","LU0965508806.USD","LU1119994496.HKD","LU2324357040.USD","LU1074936037.SGD","SG9999014914.USD","LU0661504455.SGD","SG9999017495.SGD","LU0417517546.SGD","LU0211328371.USD","LU0256863811.USD","LU0708995401.HKD","LU2211815571.USD","BK4585","LU0683600562.USD","IE00B19Z9P08.USD","SG9999002232.USD","LU2362540622.SGD","IE00BFSS7M15.SGD","LU0211326755.USD","SG9999018857.SGD","LU1496350502.SGD","IE00BFXG1179.USD","LU1674673691.USD","LU1934455863.HKD","LU0708994859.HKD","LU0965509010.AUD","IE00B19Z3581.USD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","LU1732800096.USD","IE00BZ1G4Q59.USD","LU1934455194.USD","LU2360032135.SGD","BK4566","IE00BKVL7J92.USD","LU0234572021.USD","LU0316494557.USD","LU0109391861.USD","LU0823416689.USD","LU1061106388.HKD","IE00BFSS8Q28.SGD","LU1983299246.USD","LU0158827948.USD","LU1035773651.USD","BK4154","IE0002141913.USD","LU1720051108.HKD","LU1066051225.USD","SG9999013999.USD","LU1037948897.HKD","LU1066053197.SGD","LU0310799852.SGD","LU1988902786.USD","LU0553294199.USD","LU2112291526.USD","LU0795875169.SGD","IE00BSNM7G36.USD","LU1791710582.SGD","LU2125154778.USD","SG9999014906.USD","LU2361044865.SGD","LU0738911758.USD","SG9999018865.SGD","LU1037948541.HKD","LU1069347547.HKD","LU1506573853.SGD","LU2264538146.SGD","LU2362541273.HKD","IE00B4R5TH58.HKD","LU1261432733.SGD","LU0432979614.USD","LU0266013472.USD","LU2133065610.SGD","LU0320765059.SGD","LU2552382058.USD","LU0345770308.USD","BK4588","LU1674673428.USD","IE0004445015.USD","LU2087625088.SGD","LU2089283258.USD","LU0882574055.USD","LU1778281490.HKD","LU2271345857.HKD","BK4139","LU0672654240.SGD","IE00B775H168.HKD","SG9999001176.USD","IE00B7SZLL34.SGD","LU0187121727.USD","LU1551013342.USD","LU1064131342.USD","LU2236285917.USD","LU0943347566.SGD","IE00BKPKM429.USD","LU2357305700.SGD","LU2361045086.USD","IE0002270589.USD","LU0557290698.USD","LU1066051498.USD","LU2028103732.USD","LU2089984988.USD","IE00BJJMRY28.SGD","LU0310800965.SGD","LU0456855351.SGD","LU0353189763.USD","SG9999002224.SGD","LU0949170772.SGD","LU2468319806.SGD","IE00B4JS1V06.HKD","LU0861579265.USD","LU1066051811.HKD","IE00B1XK9C88.USD","LU2279689827.SGD","LU0011850046.USD","BK4532","IE00B19Z9505.USD","LU2244417387.USD","LU0203345920.USD","LU2491050154.USD","LU1023059063.AUD","LU0342679015.USD","LU2125154935.USD","LU0122379950.USD","LU0496365809.HKD","BK4533","UNHW","LU0203347892.USD","LU0689472784.USD","LU1003077747.HKD","LU1854104046.USD","LU0238689110.USD","LU0912757837.SGD","LU1670627923.USD","SG9999014898.SGD","LU2242649171.HKD","BK4581","LU0545039389.USD","LU0354030438.USD","SGXZ51526630.SGD","IE00B894F039.SGD","LU0149725797.USD","LU0289739699.SGD","LU2552382132.HKD","IE00B7KXQ091.USD","LU1720051017.SGD","LU0353189680.USD","LU1291159041.SGD","LU1267930227.SGD","SG9999014880.SGD","LU0345770993.USD","IE00B19Z3B42.SGD","LU2362541513.USD","LU0820561818.USD","SG9999001176.SGD","LU0107464264.USD","IE00B19Z9Z06.USD","LU1718418525.SGD","IE00B19Z8W00.USD","LU1323610961.USD","LU0354030511.USD","IE00BWXC8680.SGD","LU0795875086.SGD","IE0009355771.USD","LU1791710400.SGD","LU1934455277.USD","LU1814569148.SGD","LU0251132253.USD","IE00BJT1NW94.SGD","IE0005OL40V9.USD","LU0820562030.AUD","IE00B19Z8X17.USD","LU1267930730.SGD","LU1551013425.SGD","LU2461242641.AUD","LU0787776722.HKD","LU1854103824.USD","LU1153585028.USD","LU1914381329.SGD","LU0211326839.USD","LU0158827781.USD","LU0058720904.USD","LU2089284900.SGD","LU0079474960.USD","IE00BN29S564.USD","LU1084165304.USD","LU0128525929.USD","LU0128525689.USD","LU0094547139.USD"],"gpt_icon":0},{"id":"2602514996","title":"NewcelX AG Reports Positive Results from International Study on Stem Cell-Derived Islet Therapy for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514996","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514996?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:01","pubTimestamp":1768219262,"startTime":"0","endTime":"0","summary":"NewcelX AG has announced positive results from an international collaborative research study exploring advanced biomaterial approaches for the delivery of stem cell-derived islets in the treatment of Type 1 Diabetes. The study focused on combining stem cell biology with innovative delivery and immune protection strategies, aiming to achieve functional insulin secretion without the need for systemic immunosuppression. Results from the study have already been reported and contribute to the ongoing development of NewcelX’s investigational therapy, IsletRx. The research was supported by the Australian Foundation for Diabetes Research, the National Stem Cell Foundation of Australia, and Breakthrough T1D.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8ckSXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2601688573","title":"Newcelx Appoints DR. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601688573?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAC2JNMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2601088508","title":"Press Release: NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2601088508","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601088508?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614400,"startTime":"0","endTime":"0","summary":"ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd.  , a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board .Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes.NewCelX Ltd.  is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodege","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NCEL\",params:#limit:6,delay:false,,,undefined,":[]}}